Loading stock data…
$4.11-0.04 (-0.96%)
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Arbutus Biopharma Corporation in the Healthcare sector is trading at $4.11 with a market capitalization of $716M. Wall Street consensus targets $5.38 (1 analysts), implying a +30.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $5.45, remaining 9.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.01M↓ | $179.13M↑ | $1.05M↑ | $529,000↓ | $10.74M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.75M↓ | $169.12M↑ | -$7.64M↑ | -$8.29M↓ | $1.91M |
| Net Income | -$5.14M↓ | $169.69M↑ | -$3.76M↑ | -$7.74M↓ | $2.52M |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-...